Abstract
To achieve early detection and specific cancer treatment, we propose the use of multivalent interactions in which a series of binding events leads to increased affinity and consequently to selectivity. Using melanotropin (MSH) ligands, our aim is to target melanoma cells which overexpress melanocortin receptors. In this study, we report the design and efficient synthesis of new trivalent ligands bearing MSH ligands. Evaluation of these multimers on a cell model engineered to overexpress melanocortin 4 receptors (MC4R) showed up to a 350-fold increase in binding compared to the monomer, resulting in a trivalent construct with nanomolar affinity starting from a micromolar affinity ligand. Cyclic adenosine monophosphate (cAMP) production was also investigated, leading to more insights into the effects of multivalent compounds on transduction mechanisms.
Original language | English (US) |
---|---|
Pages (from-to) | 7375-7384 |
Number of pages | 10 |
Journal | Journal of Medicinal Chemistry |
Volume | 54 |
Issue number | 20 |
DOIs | |
State | Published - Oct 27 2011 |
ASJC Scopus subject areas
- Molecular Medicine
- Drug Discovery